Astellas Pharma Inc. has been the centerpiece of significant developments. The
U.S. FDA approved the expanded label for Astellas'
IZERVAY for Geographic Atrophy, but Astellas suffered a setback as an employee was indicted by
China's prosecutors. Multiple developments were reported regarding Astellas' management structure, including several changes.
Collaboration with
Pfizer resulted in long-term efficacy in first-line treatment of advanced or metastatic urothelial cancer.
Strategic initiatives were set up in
Tanzania, and farallon Capital built over a 3% stake in the pharma company. A
new drug application for Avacincaptad Pegol was submitted in Japan, and several partnerships were formed, notably with
AviadoBio and
Sangamo Therapeutics. Notably, a
$2.2bn gene therapy deal was penned with AviadoBio Ltd. Several of its therapies received regulatory approvals, while some faced challenges. Lastly,
innovative collaborations to accelerate drug discovery were announced, and the establishment of new state-of-the-art centers indicated Astellas' commitment to delivering breakthrough therapies.
Astellas Pharma Inc. News Analytics from Wed, 31 May 2017 16:44:13 GMT to Sat, 15 Feb 2025 01:20:34 GMT -
Rating 2
- Innovation 6
- Information 5
- Rumor -3
